Court dismisses plaintiffs expert testimony (Il Sole 24 Ore Radiocor) - London, 16 Aug - The UK pharmaceutical group GSK said that the Florida State Court ruled in favour of GSK and other defendants, excluding plaintiff's experts' general and specific causation testimony that the heartburn drug ranitidine, sold under the name Zantac among others, was a significant risk factor for prostate cancer in the Wilson case.

The court's ruling is "consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer," according to GSK.

"In excluding plaintiffs' expert testimony as unreliable, GSK will now seek dismissal of the upcoming Wilson case in Florida - whereby plaintiffs alleged a causal link between ranitidine and prostate cancer," it added.

AAA-Web

(RADIOCOR) 16-08-24 08:56:21 (0126) 5 NNNN